Thiyagarajan, Durairaj http://orcid.org/0000-0003-2487-3415
Huck, Benedikt http://orcid.org/0000-0003-3111-6009
Nothdurft, Birgit
Koch, Marcus
Rudolph, David
Rutschmann, Mark
Feldmann, Claus http://orcid.org/0000-0003-2426-9461
Hozsa, Constantin http://orcid.org/0000-0001-7766-3644
Furch, Marcus
Besecke, Karen F. W.
Gieseler, Robert K. http://orcid.org/0000-0002-3064-8516
Loretz, Brigitta http://orcid.org/0000-0003-0057-5181
Lehr, Claus-Michael http://orcid.org/0000-0002-5864-8462
Funding for this research was provided by:
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
Article History
Accepted: 25 May 2021
First Online: 8 June 2021
Declarations
:
: All authors have seen and approved the publication.
: MF and RKG are shareholders of Rodos Biotarget GmbH, which holds intellectual propriety rights on the company’s targeted nanocarrier technology. All other authors declare no conflict of interest.